Table 1. Odds for drugs being bilayer... | Rockefeller University Press

Table 1.

Odds for drugs being bilayer active or likely cytotoxic vs. ALogP/PSA

	Odds for drugs having 1.25 ≤ NormRate/NormRate < 1.25
	PSA ≤ 75 Å²	PSA > 75 Å²
ALogP ≤ 3	6/38 = 0.16	32/61 = 0.52
ALogP > 3	99/72 = 1.38	58/34 = 1.71
	Odds for drugs having $\frac{{CC}_{20} < 50 µ M}{50 µ M \leq {CC}_{20}}$
	PSA ≤ 75 Å²	PSA > 75 Å²
ALogP ≤ 3	25/19 = 1.32	59/34 = 1.74
ALogP > 3	129/41 = 3.15	69/21 = 3.29

	Odds for drugs having 1.25 ≤ NormRate/NormRate < 1.25
	PSA ≤ 75 Å²	PSA > 75 Å²
ALogP ≤ 3	6/38 = 0.16	32/61 = 0.52
ALogP > 3	99/72 = 1.38	58/34 = 1.71
	Odds for drugs having $\frac{{CC}_{20} < 50 µ M}{50 µ M \leq {CC}_{20}}$
	PSA ≤ 75 Å²	PSA > 75 Å²
ALogP ≤ 3	25/19 = 1.32	59/34 = 1.74
ALogP > 3	129/41 = 3.15	69/21 = 3.29

Top: The odds ratio for a drug being bilayer-modifying (having 1.25 ≤ NormRate) is 11-fold higher (95% CI: 4.1–28.2) for drugs with ALogP > 3 and PSA > 75 Å², relative to drugs with ALogP ≤ 3 and PSA ≤ 75 Å². Bottom: The odds ratio for a drug being cytotoxic (having HepG2 CC₂₀ < 50 µM) is 2.5-fold higher (95% CI: 1.1–5.6) for drugs with ALogP > 3 and PSA > 75 Å², relative to drugs with ALogP ≤ 3 and PSA ≤ 75 Å². We only have HepG2 CC₂₀ information for 397 of the 400 drugs in the Pathogen Box.

[ViewLarge]